A UK panel consensus on the initiation of aripiprazole for the treatment of bipolar mania

International Journal of Psychiatry in Clinical Practice

Volumn 16, Issue 4, 2012, Pages 244-258

  Dratcu, Luiz ^a   Bobmanuel, Sotonte ^b   Davies, Wendy ^c   Farmer, Alan ^d   George, Mohan ^e   Rana, Tanvir ^f   Singh, Mala ^g   Turner, Martin ^h  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b BURNLEY GENERAL HOSPITAL   (United Kingdom)

^c WHITCHURCH HOSPITAL   (United Kingdom)

^d Worcestershire Early Intervention Service   (United Kingdom)

^e Oleaster National Centre for Mental Health   (United Kingdom)

^f STAFFORDSHIRE UNIVERSITY   (United Kingdom)

^g CENTRAL AND NORTH WEST LONDON NHS FOUNDATION TRUST   (United Kingdom)

^h Auchinlea CMHT   (United Kingdom)

Author keywords

Acute mania; Aripiprazole; Atypical antipsychotic; Bipolar disorder; Bipolar mania

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; HALOPERIDOL; HISTAMINE H1 RECEPTOR; LITHIUM; LORAZEPAM; MOOD STABILIZER; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; VALPROIC ACID; ZIPRASIDONE;

ACCIDENTAL INJURY; ACUTE DISEASE; ADJUVANT THERAPY; AGITATION; AKATHISIA; ANXIETY; BINDING AFFINITY; BIPOLAR MANIA; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; CONSTIPATION; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; HYPERTENSION; INSOMNIA; INSULIN RESISTANCE; LIMB PAIN; MONOTHERAPY; MUSCLE RIGIDITY; NAUSEA; PATIENT COMPLIANCE; PATIENT DECISION MAKING; PATIENT MONITORING; PHARYNGITIS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOPHARMACOTHERAPY; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; TREATMENT RESPONSE; TREMOR; UNITED KINGDOM; URINARY TRACT INFECTION; VAGINITIS; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ACUTE DISEASE; ANHEDONIA; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; LONG-TERM CARE; METABOLIC DISEASES; PATIENT PARTICIPATION; PIPERAZINES; PSYCHOMOTOR AGITATION; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TREATMENT OUTCOME;

EID: 84866362554     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2012.709865     Document Type: Review

References (57)

1. Fountoulakis K N, V ieta E. T reatment of bipolar disorder: A systematic review of available data and clinical perspectives . Int J Neuropsychopharmacol 2008; 11 : 999-1029 .
2. McIntyre R S. L ong-term treatment of bipolar disorder in adults. J Clin Psychiatry 2011 ; 72 : E06 .
3. Derry S, M oore RA. A typical antipsychotics in bipolar disorder: Systematic review of randomised trials. BMC Psychiatry 2007; 7 : 40 .
4. Goodwin GM; Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: Revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23 : 346-88 .
5. Ertugrul A, M eltzer H Y. A ntipsychotic drugs in bipolar disorder. Int J Neuropsychopharmacol 2003; 6 : 277-84 .
6. National Institute for Health and Clinical Excellence. NICE Clinical Guideline 38: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. July 2006. Available at http://www.nice.org.uk/nicemedia/ live/10990/30193/30193.pdf. Accessed 12 December 2011.
7. Yatham LN, K ennedy SH, S chaffer A, P arikh SV, B eaulieu S, O ' Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2009. Bipolar Disord 2009; 11 : 225-55 .
8. Grunze H, V ieta E, G oodwin GM, B owden C, L icht RW, Moller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009; 10 : 85-116 .
9. SPC. Aripiprazole Summary of Product Characteristics. Bristol-Myers Squibb and Otsuka Pharmaceutical Europe Ltd, 2009. Available at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000471/WC500020170.pdf. Accessed 12 December 2011.
10. Correll CU. A ssessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 2008; 69(Suppl 4) : 26-36 .
11. Jordan S, K oprivica V, C hen R, T ottori K, K ikuchi T, A ltar CA, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002; 441 : 137-40 . (Pubitemid 34626163)
12. Taylor DM. A ripiprazole: A review of its pharmacology and clinical use. Int J Clin Pract 2003; 57 : 49-54 . (Pubitemid 36181749)
13. Jordan S, K oprivica V, D unn R, T ottori K, K ikuchi T, A ltar CA, et al. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004; 483 : 45-53 . (Pubitemid 38056603)
14. Burris KD, M olski T F, X u C, R yan E, T ottori K, K ikuchi T, et al. Aripiprazole, a novel antipsychotic, is a high-affi nity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302 : 381-9 . (Pubitemid 34680462)
15. Tadori Y, F orbes RA, M cQuade RD, K ikuchi T. C haracterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Eur J Pharmacol 2008; 597 : 27-33
16. Stahl S M. D opamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, ' Goldilocks ' actions at dopamine receptors. J Clin Psychiatry 2001; 62 : 841-2 . (Pubitemid 33131168)
17. Tamminga CA, C arlsson A. P artial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord 2002; 1 : 141-7 .
18. Fagiolini A, N itti M, F orgione R N, M arra F S, C asamassima F. Aripiprazole for the treatment of bipolar disorder: A review of current evidence. Expert Opin Pharmacother 2011; 12 : 473-88 .
19. Shapiro DA, R enock S, A rrington E, C hiodo LA, L iu LX, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28 : 1400-11 (Pubitemid 41070874)
20. Chew M L, M ulsant B H, P ollock B G, L ehman M E, G reenspan A, Kirshner MA, et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 2006; 88 : 63-72 . (Pubitemid 44693242)
21. Masand P S, C ulpepper L, H enderson D, L ee S, L ittrell K, Newcomer JW, et al. Metabolic and endocrine disturbances in psychiatric disorders: A multidisciplinary approach to appropriate atypical antipsychotic utilization. CNS Spectr 2005; 10(Suppl 14) : 1-15 . (Pubitemid 41531972)
22. Haddad PM, S harma SG. A dverse effects of atypical antipsychotics: Differential risk and clinical implications. CNS Drugs 2007; 21 : 911-36 . (Pubitemid 47557106)
23. Henderson DC, D oraiswamy P M. P rolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry 2008; 69(Suppl 1) : 32-44 .
24. Hanssens L, L ' I talien G, L oze JY, M arcus RN, P ans M, Kerselaers W, et al. The effect of antipsychotic medication on sexual function and serum prolactin levels in communitytreated schizophrenic patients: Results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry 2008; 8 : 95 .
25. Montejo A L, Riesgo Y, Luque J, Barber I; Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. Observational, open-label, prospective multicenter study of sexual function in patients starting treatment with aripiprazole. Actas Esp Psiquiatr 2010; 38 : 13-21 .
26. Zarate C A Jr. A ntipsychotic drug side effect issues in bipolar manic patients. J Clin Psychiatry 2000; 61(Suppl 8) : 52-61
27. Vinogradov S, F isher M, W arm H, H olland C, K irshner MA, Pollock BG, et al. The cognitive cost of anticholinergic burden: Decreased response to cognitive training in schizophrenia. Am J Psychiatry 2009; 166 : 1055-62 .
28. Lebovitz HE. M etabolic consequences of atypical antipsychotic drugs. Psychiatr Q 2003; 74 : 277-90 . (Pubitemid 38115322)
29. Keck PE Jr, C alabrese JR, M cIntyre RS, M cQuade RD, Carson WH, Eudicone JM, et al; Aripiprazole Study Group. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: A 100-week, double-blind study versus placebo. J Clin Psychiatry 2007; 68 : 1480-91 . (Pubitemid 350073394)
30. De Fazio P, G irardi P, M aina G, M auri MC, M auri M, Monteleone P, et al. Aripiprazole in acute mania and longterm treatment of bipolar disorder: A critical review by an Italian working group. Clin Drug Investig 2010; 30 : 827-41 .
31. Marcus R, K han A, R ollin L, M orris B, T imko K, C arson W, et al. Effi cacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: A multicenter, double-blind, randomized study. Bipolar Disord 2011; 13 : 133-44 .
32. Naber D, L ambert M. A ripiprazole: A new atypical antipsychotic with a different pharmacological mechanism. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28 : 1213-9 . (Pubitemid 39592919)
33. Kane JM, S harif Z A. A typical antipsychotics: Sedation versus effi cacy. J Clin Psychiatry 2008; 69(Suppl 1) : 18-31 .
34. IM SPC. A ripiprazole 7.5 mg/mL solution for injection (intramuscular) Summary of Product Characteristics. Bristol-Myers Squibb and Otsuka Pharmaceutical Europe Ltd, 2011. Available at http://www.medicines.org.uk/EMC/ medicine/20802/SPC/Abilify - 7.5 - mg - ml - solution - for -injection - (intramuscular) - (Bristol-Myers - Squibb -Pharmaceuticals - Ltd)/. Accessed 12 December 2011.
35. Keck PE Jr, M arcus R, T ourkodimitris S, A li M, L iebeskind A, Saha A, et al; Aripiprazole Study Group. A placebocontrolled, double-blind study of the effi cacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160 : 1651-8 . (Pubitemid 41079552)
36. Sachs G, S anchez R, M arcus R, S tock E, M cQuade R, Carson W, et al; Aripiprazole Study Group. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: A 3-week placebo-controlled study. J Psychopharmacol 2006; 20 : 536-46 . (Pubitemid 43875183)
37. Keck P E, Orsulak P J, Cutler A J, Sanchez R, Torbeyns A, Marcus RN, et al; CN138-135 Study Group. Aripiprazole monotherapy in the treatment of acute bipolar I mania: A randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord 2009; 112 : 36-49 .
38. El Mallakh RS, V ieta E, R ollin L, M arcus R, C arson WH, McQuade R. A comparison of two fi xed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007). Eur Neuropsychopharmacol 2010; 20 : 776-83
39. Young A H, O ren D A, L owy A, M cQuade RD, M arcus R N, Carson WH, et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psychiatry 2009; 194 : 40-8 .
40. Vieta E, B ourin M, S anchez R, M arcus R, S tock E, M cQuade R, et al; Aripiprazole Study Group. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: Double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005; 187 : 235-42 . (Pubitemid 41306104)
41. Keck P E Jr, C alabrese J R, M cQuade R D, C arson W H, Carlson BX, Rollin LM, et al; Aripiprazole Study Group. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 67 : 626-37 . (Pubitemid 43764240)
42. Vieta E, T 'j oen C, M cQuade R D, C arson WH Jr, Marcus RN, Sanchez R, et al. Effi cacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: A placebo-controlled study. Am J Psychiatry 2008; 165 : 1316-25 .
43. Vieta E, O wen R, B audelet C, M cQuade R D, S anchez R, Marcus RN, et al. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: A 46-week, open-label extension following a 6-week double-blind study. Curr Med Res Opin 2010; 26 : 1485-96 .
44. Zimbroff D L, M arcus R N, M anos G, S tock E, M cQuade RD, Auby P, et al. Management of acute agitation in patients with bipolar disorder: Effi cacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 2007; 27 : 171-6 . (Pubitemid 46594934)
45. El Mallakh RS, M arcus RN, B audelet C, M cQuade RD, Carson WH, Owen R, et al. A 52-week, double-blind safety and effi cacy evaluation of aripiprazole monotherapy versus lithium in bipolar disorder (CN138-135LT). Poster (P63) presented at the 8th International Conference on Bipolar Disorder, June 25-27 2009, Pittsburgh, PA, USA .
46. Rana TA, M alik T. C linical trials to clinical practice: Retrospective analysis of 25 patients with bipolar mania treated with aripiprazole. Prog Neurol Psychiatry Case Notes 2010; 14(5 Suppl) : 1-8 .
47. Fountoulakis KN, V ieta E. E ffi cacy and safety of aripiprazole in the treatment of bipolar disorder: A systematic review. Ann Gen Psychiatry 2009; 8 : 16 .
48. Muzina D J. T reatment and prevention of mania in bipolar I disorder: Focus on aripiprazole. Neuropsychiatr Dis Treat 2009 ; 5 : 279 - 88 .
49. Liemburg E, A leman A, B ous J, H ollander K, K negtering H. An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being. Pharmacopsychiatry 2011; 44 : 109-13 .
50. Chung A K, C hua SE. E ffects on prolongation of Bazett' s corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: A meta-analysis. J Psychopharmacol 2011; 25 : 646-66 .
51. Goodwin G M, A bbar M, S chlaepfer TE, G runze H, L icht RW, Bellivier F, et al. Aripiprazole in patients with bipolar mania and beyond: An update of practical guidance. Curr Med Res Opin 2011; 27 : 2285-99 .
52. C, K hwaja M G. W hat is new in rapid tranquillisation? J Psychiatr Intens Care 2011; 7 : 91-101 .
53. National Institute for Health and Clinical Excellence. N ICE Clinical Guideline 25: Violence: The short-term management of disturbed/violent behaviour in in-patient psychiatric settings and emergency departments. February 2005. Available at http://publications.nice.org.uk/violence-cg25. Accessed 30 April 2012.
54. Day R K. P sychomotor agitation: Poorly defi ned and badly measured. J Affect Disord 1999; 55 : 89-98 .
55. American Psychiatric Association. P ractice guidelines for the treatment of patients with schizophrenia, 2nd edition, 2004. Available at http://www.psychiatryonline.com/pracGuide/pracGuideTopic-6.aspx. Accessed 12 December 2011.
56. Hirose S. T he causes of underdiagnosing akathisia. S chizophr Bull 2003; 29 : 547-58 .
57. Sullivan G, B ienroth M, J ones M, M illar H, R atna L, Taylor D, et al. Practical prescribing with aripiprazole in schizophrenia: Consensus recommendations of a UK multidisciplinary panel. Curr Med Res Opin 2007; 23 : 1733-44 . (Pubitemid 47122182)